Evelyn K. Bordeaux

Evelyn K. Bordeaux

Auto-generated profile, based on publicly available information

Evelyn K. Bordeaux

University of Colorado Anschutz Medical Campus

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
DRDeviyani M. Rao
Deviyani M. Rao
MSMadeleine Shackleford
Madeleine Shackleford
EBEvelyn K. Bordeaux
Evelyn K. Bordeaux
JSJoseph L Sottnik
Joseph L Sottnik
RFRebecca L. Ferguson
Rebecca L. Ferguson
MSMatthew Sikora
Matthew Sikora
Porcupine O-acyltransferase (PORCN) is considered essential for Wnt secretion and signaling. However, we observed that PORCN inhibition does not phenocopy the effects of WNT4 knockdown in WNT4-dependent breast cancer cells. This suggests a unique relationship between PORCN and WNT4 signaling. To examine the role of PORCN in WNT4 signaling, here we overexpressed WNT4 or WNT3A in breast cancer, ovarian cancer, and fibrosarcoma cell lines. Conditioned medium from these lines and co-culture systems were used to assess the dependence of Wnt secretion and activity on the critical Wnt secretion proteins PORCN and Wnt ligand secretion mediator (WLS). We observed that WLS is universally required for Wnt secretion and paracrine signaling. In contrast, the dependence of WNT3A secretion and activity on PORCN varied across the cell lines, and WNT4 secretion was PORCN-independent in all models. Surprisingly, WNT4 did not exhibit paracrine activity in any tested context. Absent the expected paracrine activity of secreted WNT4, we identified cell-autonomous Wnt signaling activation by WNT4 and WNT3A, independent of PORCN or Wnt secretion. The PORCN-independent, cell-autonomous Wnt signaling demonstrated here may be critical in WNT4-driven cellular contexts or in those that are considered to have dysfunctional Wnt signaling.

30 May 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
DRDeviyani M. Rao
Deviyani M. Rao
EBEvelyn K. Bordeaux
Evelyn K. Bordeaux
TYTomomi M. Yamamoto
Tomomi M. Yamamoto
BBBenjamin Bitler
Benjamin Bitler
MSMatthew Sikora
Matthew Sikora
RFRebecca L Ferguson
Rebecca L Ferguson
The enzyme PORCN is considered essential for Wnt secretion and signaling, however, we observed PORCN inhibition did not phenocopy the effects of WNT4 knockdown in WNT4-dependent breast cancer cells. This suggests a unique relationship between PORCN and WNT4 signaling. To examine the role of PORCN in WNT4 signaling, WNT4 or WNT3A were over-expressed in breast and ovarian cancer, and fibrosarcoma cell lines. Conditioned medium from these lines, and co-culture systems, were used to assess the dependence of Wnt secretion and activity on critical Wnt secretion proteins PORCN and WLS. We observed that WLS was universally required for Wnt secretion and paracrine signaling. In contrast, the dependence of WNT3A secretion and activity on PORCN varied across cell lines, and WNT4 secretion was PORCN-independent in all models. Surprisingly, WNT4 did not present paracrine activity in any tested context. Absent the expected paracrine activity of secreted WNT4, we identified cell autonomous Wnt signaling activation by WNT4 and WNT3A, independent of PORCN or secretion. The PORCN-independent, cell-autonomous Wnt signaling demonstrated herein may be critical in WNT4-driven cellular contexts, or those that are otherwise considered to have dysfunctional Wnt signaling. Summary Statement: Wnt proteins can mediate an atypical mode of cell-autonomous signaling, distinct from paracrine signaling, that is independent of both palmitoylation by PORCN and Wnt secretion.

27 June 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
MSMadeleine Shackleford
Madeleine Shackleford
DRDeviyani M. Rao
Deviyani M. Rao
EBEvelyn K. Bordeaux
Evelyn K. Bordeaux
HHHannah M. Hicks
Hannah M. Hicks
SOSteffi Oesterreich
Steffi Oesterreich
MSMatthew Sikora
Matthew Sikora
Invasive lobular carcinoma of the breast (ILC) is strongly estrogen-driven and represents a unique context for estrogen receptor (ER) signaling. In ILC, ER controls the expression of the Wnt ligand WNT4, which is critical for endocrine response and anti-estrogen resistance. However, signaling mediated by WNT4 is poorly understood. We utilized reverse phase protein array (RPPA) to characterize ER and WNT4-driven signaling in ILC cells and identified that WNT4 mediates downstream mTOR signaling via S6K. Additionally, independent of mTOR/S6K, ER and WNT4 control levels of MCL-1, which alters mitochondrial function. In this context, WNT4 knockdown caused decreased ATP production and increased mitochondrial fragmentation. WNT4 regulation of both mTOR signaling and MCL-1 were also observed in antiestrogen resistant models of ILC. Further, we identified that high WNT4 expression is associated with similar mTOR pathway activation in serous ovarian cancer tumors, suggesting that WNT4 signaling is important in multiple tumor types. The identified downstream pathways offer insight in to WNT4 signaling and represent potential targets to overcome anti-estrogen resistance for patients with ILC.

16 December 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
EBEvelyn K. Bordeaux
Evelyn K. Bordeaux
JSJoseph L Sottnik
Joseph L Sottnik
SMSanjana Mehrotra
Sanjana Mehrotra
SFSarah E. Ferrara
Sarah E. Ferrara
AGAndrew E. Goodspeed
Andrew E. Goodspeed
MSMatthew Sikora
Matthew Sikora
Invasive lobular carcinoma (ILC) is the most common histological subtype of breast cancer, and nearly all ILC tumors express estrogen receptor alpha (ER). However, clinical and laboratory data suggest ILC are strongly estrogen-driven but not equally sensitive to anti-estrogen therapies. We hypothesized that ILC-specific ER transcriptional co-regulators mediate ER functions in ILC and anti-estrogen resistance, and profiled ER-associated proteins by mass spectrometry. Three ER+ ILC cell lines, MDA MB 134VI, SUM44PE, and BCK4, were compared to published data from ER+ invasive ductal carcinoma (IDC) cell lines, and we examined whether siRNA knockdown of identified proteins suppressed ER-driven proliferation in ILC cells. This approach found mediator of DNA damage checkpoint 1 (MDC1), a key tumor suppressor in DNA damage response (DDR), as a putative novel ER co-regulator in ILC. We confirmed ER:MDC1 interaction was specific to ILC cell lines versus IDC cells, and found MDC1 knockdown suppressed ILC cell proliferation and suppressed tamoxifen resistance in MDA MB 134VI. Using RNA-sequencing, we found that in ILC cells, MDC1 knockdown broadly dysregulates the estrogen-driven ER transcriptome, with ER:MDC1 target genes enriched for hormone-response-elements in their promoter regions. Importantly, our data are inconsistent with MDC1 regulating ER via MDC1 DDR and tumor suppressor functions, but instead suggest a novel oncogenic role for MDC1 in mediating ER transcriptional activity as a co-regulator. Supporting this, in breast tumor tissue microarrays MDC1 protein was frequently low or absent in IDC or ER-ILC, but MDC1 loss is rare in ER+ ILC. ER:MDC1 interaction and MDC1 co-regulator functions may underlie cell type-specific ER functions in ILC, and serve as important biomarkers and therapeutic targets to overcome anti-estrogen resistance in ILC.